upcoming digital currency People also ask

Shenzhen Holdings: Auditor replacement: PricewaterhouseCoopers resigned and Ernst & Young took over. On December 10th, Shenzhen Holdings (00604.HK) announced that according to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, PricewaterhouseCoopers agreed to resign as the auditor of Shenzhen Holdings with effect from December 10th, 2024. At the same time, the board of directors of Shenzhen Holdings decided to appoint Ernst & Young as the new auditor of the company, which will also take effect from December 10, 2024 until the end of the next annual general meeting.Everbright Securities: The effect of trade-in subsidy for the whole year is much better than expected. Everbright Securities released a research report saying that the Politburo proposed to implement more relaxed policies, vigorously boost consumption and lead the development of new quality productivity. The intelligent direction of the automobile industry not only conforms to the development tone, but also plays an important role in boosting consumption. At the same time, the industry involves the "two new" themes of large-scale equipment renewal and trade-in of consumer goods, and the bank continues to be optimistic about investment opportunities in the automobile sector driven by favorable policies.In 2024, the number of cases of dengue fever in Brazil exceeded 6.76 million. On December 10, local time, according to the latest data from the Brazilian Ministry of Health, this year, the number of suspected and confirmed cases of dengue fever in Brazil rose to 6,763,743, and the number of deaths rose to 5,950, with another 1,091 deaths to be verified. In 2024, the number of cases of dengue fever infection in Brazil reached a record high since the country's epidemic record, which was three times that of 2023. The death toll of dengue fever has also reached a record high, four times that of 2023. The regions with the highest infection rates are federal capital territory, minas gerais, Balana and Sã o Paulo.

On the morning of December 9, Leo, Party Secretary and Chairman of Shanghai Electric Group, went to Seoul, South Korea, and held talks with Zhao Xianjun, President of Xiaoxing Group. The two sides had in-depth exchanges on joint ventures and cooperation in the field of new energy. During the talks, the two sides also discussed the cooperation potential in the fields of hydrogen energy and power grid equipment, sought cooperation opportunities in technology research and development, project investment and market development, and jointly explored cooperative development models in the field of new energy to meet the challenges brought by global energy transformation.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.13 shares registered today, Hengxuan Technology, Xiamen Bank and Deshi shares have the strongest dividends. According to the statistics of the equity distribution plan of listed companies, 13 A shares registered today. Among them, 13 shares intend to pay dividends. In terms of dividends, 13 stocks paid dividends in date of record on December 11th. Hengxuan Technology, Xiamen Bank and Deshi Co., Ltd. have the strongest dividends, with dividends of 7.60 yuan for every 10 shares, 1.5 yuan and 1.2 yuan respectively. In addition, there are 5 shares that have thrown out dividend payout plans, among which Contemporary Amperex Technology Co., Limited, Taotao Auto Industry and Hite Bio have the strongest dividend payout, with dividends of 12.3 yuan for every 10 shares, 5 yuan and 1.3 yuan respectively.

ADB lowered the growth forecast of developing economies in the Asia-Pacific region to maintain China's economic growth forecast. On December 11th, the Asian Development Bank issued the Asia Development Outlook 2024 (December Edition). According to the report, the development momentum in the Asia-Pacific region is steady, but as US President-elect Trump is about to take office, changes in his trade, finance and immigration policies may inhibit the development of the Asia-Pacific region and aggravate inflation. ADB lowered its growth forecast for developing economies in the Asia-Pacific region from the previous 5.0% to 4.9% in 2024, and from the previous 4.9% to 4.8% in 2025. China's economic growth is expected to remain at 4.8% and 4.5% in 2024 and 2025 respectively, which is the same as before.China Huaneng and Huawei signed a strategic cooperation agreement. On December 6th, China Huaneng Group Co., Ltd. (hereinafter referred to as "Huaneng") and Huawei Technologies Co., Ltd. (hereinafter referred to as "Huawei") signed a strategic cooperation agreement. Wen Shugang, Chairman and Party Secretary of Huaneng Group, held talks and witnessed the signing of the contract with Meng Wanzhou, rotating chairman and CFO of Huawei, and jointly unveiled Huaneng-Huawei New Energy joint innovation lab. According to the agreement, the two sides will continue to deepen strategic cooperation in the fields of clean energy cooperation, digital transformation cooperation, the establishment of joint innovation lab, and corporate culture exchange.GM will withdraw from the driverless taxi business, and the Cruise self-driving car division of GM will withdraw from the driverless taxi business. According to a statement on Tuesday, Cruise and GM's technical team will be combined to focus on developing autonomous driving and advanced driver safety technology for GM's future sales models. GM said that it will no longer provide funds for the development of self-driving taxis "considering the large amount of time and resources needed to expand its business scale and the increasingly fierce competition in the self-driving taxi market". The company said that giving up the development of self-driving taxis will save it more than $1 billion in annual costs.